However, upon grouping the breast cancer patients by their estrogen-receptor status, no consistent trend was observed between patients with no relapse during the follow-up period and patients with metastatic relapse during the follow-up period for both gene sets, Figure S4 in Supplementary Material. This evidence concerns the gene ESR1 and breast carcinoma.